We have identi®ed a retinoic acid response element (RARE) within a neural enhancer located 3 H to the Hoxd4 gene. This RARE is required for the initiation and maintenance of Hoxd4 transgene expression in neurectoderm, and for full anteriorized expression upon retinoic acid (RA) treatment. Mutations within the sequence TTTTCTG, located 2 bp downstream of the RARE, posteriorized transgene activity. However, the onset of transgene expression and its response to RA were indistinguishable from wild type. While the TTTTCTG motif resembles a CDX binding site, human CDX1 protein did not interact with this element in vitro. Three additional regions were also shown to control transgene expression in neurectoderm, establishing that multiple elements constitute the Hoxd4 neural enhancer. q
Introduction
The Hox genes of vertebrates, and their counterparts in Drosophila and other animals, specify regional identity along the anteroposterior (AP) axis of the embryonic trunk, limbs and other structures. Their expression is spatially and temporally restricted such that speci®c HOX products appropriately regulate cellular target genes at the right time and place. Hox gene expression domains are characterized by discrete anterior expression borders in both neurectoderm and mesoderm (McGinnis and Krumlauf, 1992; Krumlauf, 1994; Sekimoto et al., 1998) . The importance of proper Hox gene expression in vertebrates has been con®rmed by gain-of-function and loss-of-function mutations. The alteration of Hox gene expression in the mouse leads to embryonic malformations which can sometimes be interpreted as homeotic transformations resulting from altered AP positional identity. Ectopic expression of a Hox gene in a region more anterior to its normal expression domain results in posterior transformations (Lufkin et al., 1992; McLain et al., 1992; Zhang et al., 1994) . Null mutations often lead to anterior transformation although posterior transformations can also occur (Krumlauf, 1994; Manak and Scott, 1994) . Thus, the regulation of Hox gene expression is critical for normal development.
In human and mouse, 39 Hox genes have been identi®ed. They are organized into four clusters (Krumlauf, 1994; Zeltser et al., 1996) . These genes are believed to have arisen from a single ancestral cluster by two duplication events during evolution. As a result, genes falling at the same relative position between the clusters are highly related by sequence, expression pattern, and function. Such groups of highly related genes found at the same relative position between clusters are called paralogs. There are 13 paralog groups in vertebrates. The expression of Hox genes is often correlated with their genetic position in the cluster, such that a more 3 H gene is expressed more anteriorly and earlier during embryogenesis, and is more sensitive to induction by retinoic acid (RA) (Duboule, 1994; Sekimoto et al., 1998) . The mechanisms by which Hox gene expression is regulated both spatially and temporally are not yet fully elucidated.
A few upstream regulators have been identi®ed by promoter analysis in transgenic assays. HOX proteins have been shown to autoregulate or cross regulate Hox genes, as in the cases of Hoxb1 (Zhang et al., 1994; Po Èpperl et al., 1995) , Hoxb2 (Maconochie et al., 1997) , Hoxa4 (Packer et al., 1998) , Hoxb4 , and Hoxd4 (Po Èpperl and Featherstone, 1992) . The zinc ®nger protein KROX20 regulates Hoxa2 , and Hoxb2 (Sham et al., 1993) in rhombomere 3 (r3) and r5. AP2 family proteins control Hoxa2 in neural crest (Maconochie et al., 1999) . The Maf family protein KRML1 regulates Hoxb3 in r5 (Manzanares et al., 1997) and Hoxa3 in r5 and r6 . In addition, mammalian Polycomb group and trithorax group genes such as Bmi1 and Mll control Hox gene expression in the mouse, suggesting a functional conservation of their role in the maintenance of Hox gene expression observed in the¯y (Yu et al., 1995; van der Lugt et al., 1996; Yu et al., 1998) .
Cdx genes are the mammalian homologues of the Drosophila caudal (cad) gene. Null mutants of Cdx1 show anterior homeotic transformations of the axial skeleton and posteriorization of a number of Hox gene expression domains in the somitic mesoderm (Subramanian et al., 1995) . Functional CDX-binding sites have been identi®ed in Hoxb8 (Charite Â et al., 1998) and likely Hoxa7 (Knittel et al., 1995; Min et al., 1996; Min et al., 1998) and Hoxc8 (Shashikant et al., 1995) , and others (Subramanian et al., 1995) .
Administration of RA, the major bioactive form of vitamin A (retinol), has been shown to induce homeotic transformations along the AP axis of the mouse embryo, and alter the expression domains of numerous Hox genes (Kessel and Gruss, 1991; Conlon and Rossant, 1992) . The full response of Hoxd4 and Hoxb4 to exogenous RA is dependent on RARb (Folberg et al., 1999b) . Rarg null mutants share common phenotypes with Hoxb4 and Hoxd4 null mutant mice, partially transforming cervical vertebra 2 (C2) into C1 identity (Lohnes et al., 1993; Ramõ Ârez et al., 1993; Horan et al., 1995) . Consistent with this, Rarg synergizes with Hoxd4 for speci®cation of anterior cervical vertebrae (Folberg et al., 1999a) . RA regulates its target genes through nuclear RA receptors (RARs and RXRs) of the steroid/thyroid hormone receptor superfamily. The heterodimer of RAR and RXR speci®cally binds to retinoic acid response elements (RARE), which consist of direct repeats of the consensus sequence (PuGG/TTCA) spaced by either 2 (DR2) or 5 (DR5) nucleotides (Chambon, 1994; Mangelsdorf et al., 1994) . Functional RAREs have been identi®ed in Hoxa1 (Langston and Gudas, 1992; Frasch et al., 1995) , Hoxb1 Studer et al., 1994; Huang et al., 1998) , Hoxa4 (Packer et al., 1998) , Hoxb4 (Gould et al., 1998) and Hoxd4 (Po Èpperl and Featherstone, 1993; Morrison et al., 1996; Zhang et al., 1997) .
Genes of the fourth paralog group, including Hoxa4, Hoxb4, Hoxc4 and Hoxd4, are homologues of the Drosophila Deformed gene. Although they share similar anterior expression boundaries in the CNS and paraxial mesoderm, subtle differences have been observed in terms of anterior boundaries, levels and timing of expression and dorsalventral distribution, suggesting that the mechanisms of gene regulation have diverged (Featherstone et al., 1988; Galliot et al., 1989; Gaunt et al., 1989; Graham et al., 1991; Geada et al., 1992) . Studies on Hoxa4 regulation reveal an autoregulatory element (ARE) and a RARE in the 5
H¯a nking region (Packer et al., 1998) . The ARE is important for the maintenance of Hoxa4 transgene expression after embryonic day (E)10.5. The 5 H RARE is required for the expression of a reporter gene in peripheral nerves, gut, lung, and metanephros. An ARE and a RARE have also been mapped to the Hoxb4 3 H¯a nking region Gould et al., 1998) . The RARE is required for initiation of Hoxb4 expression, while the ARE is required later to maintain the correct anterior boundary.
As for Hoxb4, Hoxd4 is expressed at the border of r6 and r7 in the hindbrain. Hoxd4 is also expressed up to somite 5 in the paraxial mesoderm (Featherstone et al., 1988; Gaunt et al., 1989) . A 5 H RARE and an ARE have been previously mapped to the Hoxd4 5
H¯a nking region. This RARE is conserved in human HOXD4 (Po Èpperl and Featherstone, 1993; Morrison et al., 1996; Morrison et al., 1997) . The RARE of human HOXD4 has been shown to direct expression to a posterior domain in the CNS, while the mouse Hoxd4 RARE plays a minor role in directing expression to the paraxial mesoderm (Zhang et al., 1997) . However, a region found 3 H to the Hoxd4 gene (called region A) is critical for Hoxd4 expression in the CNS, and is required for the RA responsiveness of Hoxd4 transgenes (Zhang et al., 1997) . This Hoxd4 neural enhancer has been mapped to a 678 bp subfragment within region A . Here, we have more ®nely dissected this neural enhancer to reveal a 3 H DR5 type RARE and a TTTTCTG site that are required for Hoxd4-like expression in the CNS. The RARE is required for the initiation and maintenance of Hoxd4 expression, and is responsible for RA responsiveness. This Hoxd4 RARE is conserved with the RARE located 3
H to the related Hoxb4 gene. The TTTTCTG site is also required for setting the correct anterior boundary in the CNS, and is located 2 bp downstream of the RARE. We also show that three additional regions are required to recapitulate the Hoxd4 expression pattern in the CNS. These results demonstrate that the Hoxd4 neural expression pattern is regulated by multiple transcriptional elements.
Results

Deletional mapping of the Hoxd4 neural enhancer
We have previously shown that a transgene reporter spanning several kb 5 H and 3 H to the murine Hoxd4 gene (Fig. 1A , construct 1) directs lacZ expression to both the central nervous system (CNS) and paraxial mesoderm with correct anterior boundaries between r6 and r7, and somites 4 and 5, respectively. Removal of a 3 H HindIII fragment (Region A) from construct 1 to give construct 2 (Fig. 1A) abolishes expression in the CNS at E9.5, thus mapping a major neural enhancer (Zhang et al., 1997) . The homologous neural enhancer in region A of human HOXD4 has been further mapped to a 678 bp region (Fig. 1A , region CE) (Morrison et al., 1996) . To map more ®nely neural regulatory elements within this CNS enhancer, a series of deletion and point mutations in the comparable murine CE region were tested for their ability to rescue the Hoxd4 expression pattern in the CNS after insertion into construct 2. All mice were dissected at E10.5 in all transient transgenic assays. The actual developmental stage of dissected embryos was often delayed by half a day. In addition, a number of permanent transgenic lines were established.
Derivatives of region CE bearing 5 H deletions up to site H or W were fully competent to rescue Hoxd4-like expression in the CNS (Fig. 1A , constructs 3 and 4; Fig. 2A ,B). However, further deletion of 116 bp to site I posteriorized the transgene expression border in seven out of eight animals ( Fig. 1A , construct 5; Fig. 2C ). In addition, three of these seven showed markedly reduced expression levels. This maps a region required for setting the correct anterior border of Hoxd4 expression between sites W and I. Deletion from the 3 H end to site L did not affect rescue of CNS expression (Fig. 1A, construct 6; Fig. 2D ). Region CL is thus suf®cient for strong neural enhancer function under these conditions. Although 5 H deletion to site H (Fig. 1A , construct 3; Fig. 2A ) also had no effect on enhancer activity, the combination of these 5 H and 3 H deletions (Fig. 1A , construct 7; Fig. 2E ) abolished posterior expression in two out of two transgenic embryos. The anterior expression border of one of these two embryos was also posteriorized. This suggests that redundant elements do in fact lie in region C±H and L±E, and that both must be removed to affect neural enhancer activity in our assay.
A TTTTCTG site is required for setting the correct anterior expression border
While 3 H deletion of region CL to site V ( (Margalit et al., 1993) ). One of these sites was eliminated and the other truncated by deletion to site K (Fig. 1B ). However, when tested in EMSA, the upstream TTTTCTG element was not capable of binding in vitro translated human CDX1 (Fig.  3B) .
To assess the importance of these sites for neural enhancer function, we tested two ®ne mutations in the context of construct 6. Point mutation of the TTTTCTG site (Fig. 1A , construct 10; Fig. 2H ) reproducibly posteriorized the anterior border of transgene expression in the hindbrain. Moreover, expression levels in two animals were very weak. Mutation of both sites gave similar results (data not shown).
To examine the role of the upstream site in the temporal control of Hoxd4 expression, a permanent transgenic line was established with construct 10 (Fig. 1A) . As for the wildtype parental construct 1, transgene expression was activated by E8.5 (Fig. 4A) . However, at both E9.5 and E10.5, the expression border was posterior to the r6/7 boundary as seen in transient assays (Fig. 4B,D) . Interest- H region A fragment to give construct 2 almost abolishes this expression (Zhang et al., 1997) . Fragments in region CE were inserted 3 H to construct 2 to test for rescue of neural activity. Arrows, Hoxd4 promoters; bigger solid square, the previously mapped 5 H RARE (Po Èpperl and Featherstone, 1993; Zhang et al., 1997) ; smaller solid square, homeobox (HB). The restriction sites on construct 1: N, NcoI; H, HindIII; S, SphI; X, XbaI. The letters within region CE designate the primers used to make these constructs and their relative position. For constructs 10 and 11, X indicates mutation of TTTTCTG site; triangle indicates mutation of the 3 H RARE. On the left are the numbers and names of constructs used in the transgenic assay. On the right are the expression patterns in transgenic mice, whether obtained transiently or from established lines. exp, the number of transgenic mice that expressed strongly over total number of transgenic mice; border, the number of transgenic mice with an anterior boundary between r6 and 7 over the total number of transgenic mice. (B) Sequence comparison of the Hoxd4 3 H RARE region in mouse and human (Cianetti et al., 1990) , and the 3 H Hoxb4 RARE in mouse (Gould et al., 1998) . Half-arrows over sequences denote the positions of the imperfect direct repeats of the RAREs;`K' and the vertical arrow denote deletion endpoint K; the site of the TTTTCTG element is overlined. Fig. 3 . DNA-binding by putative regulatory factors in EMSA. (A) The identity of radioactively labeled double-stranded probes is given on top. In vitro translated RARb and RXRa retarded the migration of probes bearing either the Hoxa1 RARE or the presumptive Hoxd4 RARE, as indicated by the arrow. Non-speci®c binding due to components of the reticulocyte lysate is also seen just below the shifted RARE bands in all lanes except probe alone (®rst, sixth and eleventh lanes). (B) The probes identi®ed on top correspond to a known control CDX binding site (CDX) or a sequence spanning the TTTTCTG element. The TTTTCTG element is similar to a CDX binding site, but does not bind to in vitro translated human CDX1 protein. The arrow indicates the CDX1 complex that forms with the known CDX binding site. Lanes 1 and 4, probe alone. Lanes 2 and 5, unprogrammed reticulocyte lysate. ingly, 24 h after treatment with RA on E8.5 and E9.5, expression was anteriorized (Fig. 4C ,E) in a manner indistinguishable from wild-type constructs (Fig. 5C,E) . Thus, an excess of RA entirely compensates for the debilitating effects of mutations in this element.
A retinoic acid response element is a critical component of the Hoxd4 neural enhancer
Use of a second program, MatInspector (Quandt et al., 1995) (http://www.gsf.de/cgi-bin/matsearch.pl), also revealed an element with homology to a binding site for the steroid family of nuclear receptors immediately 5 H to the TTTTCTG site. This site bears strong resemblance to a RARE subsequently reported for the neural enhancer of the murine Hoxb4 gene (Gould et al., 1998) . Both the Hoxd4 and Hoxb4 elements deviate from the consensus at the same position in the 3 H half-site (Fig. 1B) . This is expected to reduce the af®nity of binding to the RAR component of the RXR´RAR heterodimer. This RARE is also conserved in human HOXD4 (Cianetti et This effect is more pronounced ventrally. RA was administered to pregnant mice at E8.5 (C) and E9.5 (E), and embryos harvested 24 h later. Despite the posteriorized expression border before treatment, administration of RA results in anteriorized expression up to r6 (C,E) and r4 (E). This pattern is highly reminiscent of the wild-type transgene in response to RA. al., 1990) except for a single base-pair substitution in the spacer separating the 5 H and 3 H binding sites for RXR and RAR, respectively. Such substitutions are not expected to affect dramatically receptor binding.
Use of this potential RARE in EMSA con®rmed that it was indeed bound by RXR´RAR heterodimers. Importantly, point mutations which abolished binding to retinoid receptors in EMSA (Fig. 3A) were likewise suf®cient to eliminate virtually all neural enhancer activity of region CL in transgenic embryos (Fig. 1A, construct 11; Fig. 2I ). Thus, a presumptive RARE is a critical component of the Hoxd4 3 H neural enhancer. The RARE is only 2 bp 5 H to the TTTTCTG site. Even though CDX failed to bind to this site in EMSA, it remained possible that CDX and retinoid receptors might cooperate to increase the af®nity of DNA-binding by one or both sets of factors. However, analysis by EMSA failed to reveal any evidence for cooperativity (data not shown).
The Hoxd4 RARE is required for both the initiation and maintenance of expression in the neural tube
To examine the role of the RARE in the temporal control of Hoxd4 expression, we generated permanent transgenic lines. We tested two lines carrying construct 6 which gives strong wild-type expression. In addition, four lines were made bearing construct 11 which is identical to construct 6 except for the inactivating mutations in the RARE. As seen earlier for construct 1, construct 6 was expressed strongly by E8.5 with a correct anterior boundary just posterior to the otic sulcus (Fig. 5A) . At E9.5, expression was strong with an anterior border that was likewise correct, lying just posterior to the otic vesicle between r6 and r7 (Fig. 5B) . Strong Hoxd4-like expression was maintained a full day later at E10.5 (Fig. 5D) . Thus, region CL contained within construct 6 is able to recapitulate Hoxd4 expression in the neural tube from early to late times of gestation. By contrast, mutation of the RARE abolished expression at E8.5 with embryos from only one out of four lines showing weak staining around E9 (data not shown; Fig. 5F ). At E9.5 (Fig. 5G) , expression was restricted to a small dorsal patch that was more intense at E10.5 (Fig. 5I) . This restricted and posteriorized expression is highly reminiscent of the transgene expression pattern previously seen with construct 2, suggesting that mutation of the RARE virtually abolishes the contribution of region CL to expression in the neural tube. Importantly, this implicates the RARE of Hoxd4 in both the initiation and maintenance of expression.
The RARE of Hoxd4 region A is required for the full response to RA
We have previously shown that RA treatment anteriorizes endogenous and transgenic Hoxd4 expression borders in the neural tube (Folberg et al., 1997; Morrison et al., 1997; Zhang et al., 1997) . To determine whether the RARE in region A of Hoxd4 is required for this response, we examined transgenic lines bearing constructs 6 or 11 for their response to RA 24 h following treatment on E8.5 and E9.5. Construct 6 displayed anteriorized expression in the CNS at 24 h post-treatment (Fig. 5C,E) . Mutation of the RARE in region A entirely abolished the RA-response at E9.5, con®rming the importance of this element in mediating retinoid signals (Fig. 5H) .
Interestingly, mutation of the RARE did not entirely abolish the response to RA following treatment on E9.5. Twenty-four hours later, the residual patch of transgene expression in the dorsal neural tube was extended to a point just anterior to the normal Hoxd4 expression border (Fig. 5J) . This ectopic expression domain was restricted to the dorsal neural tube. Together, these results show that a RARE mediates the response to RA, and that part of the RAinduced expression domain on E10.5 is mediated by one or more elements distinct from the RARE.
Discussion
Multiple elements control the expression of Hoxd4 in the embryonic CNS
Our study demonstrates that the regulatory activity of a number of elements must be integrated in order to establish the Hoxd4 expression domain in the neurectoderm. These include redundant elements in regions CH and LE, one or more elements between sites W and I, the TTTTCTG site in region KV, and a DR5 type RARE just 5
H to site K. The dissection of a number of enhancers suggests that such a modular arrangement is the norm. The study of the interferon-g enhancer and the T-cell receptor gene enhancer reveals that multiple binding sites serve to coordinate the synergistic interaction between several adjacently bound factors (Carey, 1998) . Kucharczuk et al. (1999) demonstrated that 8 out of 17 linker scanner mutations in a 258 bp MyoD core enhancer result in a partial or completely loss of the enhancer activity, suggesting multiple elements are required for MyoD expression. The expression of several Hox genes in the CNS has likewise been shown to depend on multiple elements. These include the action of a RARE with additional elements in Hoxa1 (Langston and Gudas, 1992; Frasch et al., 1995) , a positive ) and a negative ) RARE in addition to three PBX´HOX binding sites in Hoxb1 (Po Èpperl et al., 1995) , an AP2-responsive element (Maconochie et al., 1999) and KROX20 binding sites plus other elements in Hoxa2 , KROX20 binding sites and a box 1 site (Sham et al., 1993; Vesque et al., 1996) plus a PREP/ MEIS´HOX´PBX binding site in Hoxb2 (Sham et al., 1993; Ferretti et al., 1999; Jacobs et al., 1999) , a KRML1 binding site and others in Hoxa3 , KRML1 binding sites and an Ets-related activation site (Manzanares et al., 1997) plus KROX-20 binding sites (Seitanidou et al., 1997) in Hoxb3, a RARE and PBX´HOX binding site in Hoxb4 Gould et al., 1998) , a 5 H RARE and a binding site X in human HOXD4 (Morrison et al., 1996) , a 5 H enhancer containing a RARE and having autoregulatory activity, plus a 3 H neural enhancer in Hoxa4 Packer et al., 1998) , multiple AAATAA elements in Hoxa5 (Nowling et al., 1999) , and multiple CDX binding sites and other elements in Hoxb8 (Charite Â et al., 1998) . In the case of Hoxb4, a DR5 type RARE acts early to initiate expression with an appropriate anterior border (Gould et al., 1998) . While insuf®cient to sustain the anterior border, the RARE is nonetheless required to maintain expression at later times in the majority of the Hoxb4 expression domain. A PBX´HOX binding site 5 H to the Hoxb4 RARE serves to maintain the correct anterior boundary . The regulation of Hox genes is further complicated by the observation that FGF8 from the isthmus at the mid-hindbrain junction inhibits Hoxa2 expression in r1 (Irving and Mason, 2000) . Together with the inhibitory RARE mapped 5
H of Hoxb1, these data suggest that multiple positive and negative regulatory inputs act in concert to establish Hox gene expression domains.
A RARE 3 H to Hoxd4 is required for expression in neurectoderm
The RARE we have mapped 3
H to Hoxd4 is clearly evolutionarily related to that of Hoxb4 by virtue of a similar activity in the CNS, similar location 3 H to the gene, and by sequence conservation (Gould et al., 1998) . Further evidence that this element is a bona ®de RARE comes from the demonstration that it binds a RXRa´RARb heterodimer, and that mutations that abolish binding to the heterodimer in vitro severely compromise enhancer activity in neurectoderm. Additionally, the RARE is strictly required for the response to exogenous RA on E8.5, and for a full response on E9.5.
Studies on region A of Hoxb4 have identi®ed neural enhancer elements active at early (E8) and later (E9.5) times of gestation (Gould et al., 1998) . The early enhancer is dependent on the RARE homologous to that identi®ed here in the Hoxd4 gene. As for Hoxb4, we observe that the 3 H RARE of Hoxd4 is active by E8.5. Importantly, the 3 H RAREs of both Hoxd4 and Hoxb4 are also active at later time points. Mutation of the Hoxd4 and Hoxb4 RAREs virtually abolishes expression in neurectoderm at E8.5, E9.5 and E10.5 (the latter time point examined for Hoxd4 only). Thus, while these RAREs may play key roles in the initiation of Hox gene expression, they are also critical for the maintenance of Hox expression at later stages. A similar requirement for a RARE in both the initiation and maintenance of CNS expression has been demonstrated for Hoxb1 .
The RARE of Hoxb4 is not suf®cient for specifying the correct anterior boundary in neurectoderm at E9.5 and E10.5. Setting of the correct anterior border is dependent on a motif that resembles a PBX´HOX cooperative binding site. This site does not support DNA-binding by recombinant PBX and HOXB4, and in vivo is not fully dependent on the activity of EXD, the PBX homologue in¯ies . However, we have shown strong cooperative DNA-binding to this element by a PBX´HOXD4 heterodimer (K. Shanmugam and M.S. Featherstone, unpublished results) . This is consistent with the observation that both HOXB4 and HOXD4 act through an enhancer containing this element to auto-and cross-regulate a Hoxb4 transgene . By contrast, region CL of Hoxd4 does not harbor any motif resembling a PBX´HOX cooperative binding site. Moreover, if the spacing between the RARE and the PBX´HOX binding site of Hoxb4 is conserved in Hoxd4, the latter would be excluded from region CL. In addition, since mutation of the RARE also abolishes transgene expression at late times (Fig. 5I) , it suggests that the equivalent of the Hoxb4 late enhancer does not lie in the CL region (Gould et al., 1998) .
Nonetheless, region CL directs transgene expression with an anterior border that is indistinguishable from that of the endogenous Hoxd4 gene as revealed by in situ hybridization (Folberg et al., 1997) . This may indicate somewhat divergent roles for the Hoxb4 and Hoxd4 RAREs. In this light, it is interesting to note that Hoxd4 expression in the hindbrain is abolished in Rara/Rarb double mutants, while Hoxb4 expression is unaffected (Dupe Â et al., 1999) . This further supports a differential contribution of the RARE to enhancer function in these two paralogs. This is also consistent with our suggestion that Hoxd4 lacks an auto/pararegulatory element such as is found in Hoxb4.
We also note that our Hoxd4 transgenes, unlike those used to assess the function of Hoxb4 regulatory elements, contain extensive intronic and 5
H¯a nking sequences. These include a 5 H RARE that displayed neural enhancer activity in one study (Po Èpperl and Featherstone, 1993; Zhang et al., 1997) . It is possible that elements within these regions, while relatively inactive in the CNS by themselves, potentiate the function of the 3 H RARE in our Hoxd4 transgenes. This may lead to the setting and maintenance of the correct anterior expression border despite the absence of a late enhancer element such as mapped in Hoxb4. These additional elements may include PBX´HOX or HOX monomer binding sites. We have previously mapped an autoregulatory element composed of at least two HOXD4 monomer binding sites 5 H to the Hoxd4 gene (Po Èpperl and Featherstone, 1992) . These sites are conserved in human HOXD4 and direct expression in¯ies in response to the HOXD4 ortholog DEFORMED (Malicki et al., 1992) . However, the Hoxd4 3 H region A alone is suf®cient to direct Hoxd4-like transgene expression in the CNS, demonstrating that these 5 H elements are dispensable under some conditions .
So far, RAREs have only been directly associated with genes of the ®rst and fourth paralog groups. While genes of other groups may be under the control of distinct RAREs, this is not necessarily the case. For example, the RARE located 3
H to Hoxa1 has been suggested to regulate the expression of Hoxa2 as well, despite the presence of the intervening Hoxa1 gene (Dupe Â et al., 1997) . The greater distance and relative position of the RARE results in the establishment of a more posterior expression domain in Hoxa2. Along similar lines, the RAREs shown to affect the expression of Hoxb4 and Hoxd4 are located 3 H to these genes, but 5 H to the Hoxb3 and Hoxd3 genes. In fact, upstream promoters for Hoxb3 and Hoxd3 lie within the region A enhancers of their fourth group neighbors (Sham et al., 1992, C. Nolte and M.S. Featherstone, unpublished data) . Thus, these RAREs may act on both third and fourth group paralogs. Relative placement 5
H to third group genes may result in a more anterior border than when acting from a 3 H position on fourth group genes. Additionally, the action of other regulators such as CDX1, KRML1 and KROX20 are likely to in¯uence the ®nal position of the anterior expression border (see below).
After mutation of the Hoxd4 3 H RARE, RA treatment activated transgene expression in a dorsally restricted domain of the CNS with an anteriorized boundary, although the expression is usually weak. This effect was only observed after treatment on E9.5, and not after treatment on E8.5. Construct 2 does not respond to RA at either stage, indicating that the response is mediated by the CL region. Given the presence of RARE half sites in the CL region, it is tempting to speculate that cryptic RARE(s) play a role in expression in the dorsal CNS in the presence of excess RA. It is interesting to note that transgenes driven by the RARb 1/b 3 promoter are also expressed in the dorsal portion of the neural tube, suggesting that this response is mediated by RARb1/b 3 (Mendelsohn et al., 1994) . It is also possible that both RARb 1/b 3 and our transgene respond to molecules that pattern the dorso-ventral axis such as bone morphogen protein 4 (BMP4), sonic hedgehog (Shh), PAX3 and PAX7. Late activation of the transgene in the dorsal CNS suggests that limiting factors are not present until E9.5 or are induced by RA.
3.3. The TTTTCTG site is required to set the anterior border of Hoxd4 expression in the CNS Computer-assisted sequence inspection revealed a CDXlike binding site, TTTTCTG, two base pairs downstream of the Hoxd4 RARE. Although this site failed to bind in vitro translated CDX1 in EMSA, it proved important for normal expression of Hoxd4 transgenes. Upon mutation, transgene expression was considerably posteriorized to a point within the spinal cord. However, the onset of transgene expression as assessed in permanent mouse lines was unaffected by mutation of the TTTTCTG site. Although in vitro translated CDX1 protein does not bind this element, our results do not exclude the possibility that CDX-binding requires an in vivo modi®cation of the protein or an interaction with another factor. Alternatively, a novel factor may bind the TTTTCTG motif.
The proximity of the TTTTCTG site to the RARE may suggest that the transcription factor bound to this adjacent sequence cooperates with the RXR´RAR heterodimer to effect transcriptional regulation. Three other Hox-associated RAREs have likewise been shown to lie near binding sites for other factors (Ogura and Evans, 1995a,b; Morrison et al., 1996) (see above), suggesting that cooperation at one or more levels between retinoid receptors and additional factors may be a common theme in the control of Hox gene expression.
Materials and methods
Transgenic constructs
3
H and 5 H -CATCGCGACCCAGGGTACCAATTTTCTGT-TCGATT-3 H .
4.2. Production, b-galactosidase staining, and RA treatment of transgenic mice
To prepare DNA for injection, the pPolyIII backbone was removed from constructs by digestion with NotI followed by separation in a low-melt gel. The DNA fragments were puri®ed by Elutip-D columns (Schleicher and Schuell). Inbred FVB mice (Harlan, USA) were used to produce transgenic mice by standard procedures (Hogan et al., 1986) . Transgenic mice were identi®ed by PCR of yolk sac or tail DNA. Transgenic lines were mated with FVB for the maintenance of the lines, and were outbred to CD1 females (Harlan) for studies with RA. RA was administered to pregnant mice as described previously (Conlon and Rossant, 1992) . Pregnant mice were killed at appropriate stages, and embryos were dissected, stained and photographed as previously described (Zhang et al., 1997) .
Electrophoretic mobility shift assay (EMSA)
RARb (a gift from Dr Pierre Chambon) and RXRa (a gift from Dr Vincent Gigue Áre) were in vitro transcribed and translated with a T7 polymerase TnT coupled kit (Promega). The reactions were monitored by parallel reactions with [
35 S]methionine and the presence of the proteins con®rmed by sodium dodecyl sulfate±polyacrylamide gel electrophoresis. A human Cdx1 cDNA (a gift from Dr Juan Iovanna) was subcloned into the pCS21 expression vector at the EcoRI site in the polylinker of the vector. CDX1 protein was produced by translation of transcripts synthesized by SP6 polymerase (Promega). Oligonucleotides were labeled as described previously (Phelan and Featherstone, 1997) . EMSA was performed as described in Po Èpperl and Featherstone, 1993 for RXR´RAR-binding and Taylor et al. (1997) for CDX1-binding. The sequences of oligonucleotides used for EMSA (one strand) were as follows: RARE, 5 H -CAGAATCAGGTTCACCCAGAGGACAAATT; RA-RE mutation, 5 H -CAGAATCATCGCGACCCAGGGTAC-CAATT; TTTTCTG site, 5
H -GAGGACAAATTTTCTG-TTCGAT; TTTTCTG site mutation, 5
H -GAGGACAAC-CCGCGGATTCGAT; RARE and TTTTCTG site, CAG-AATCAGGTTCACCCAGAGGACAAATTTTCTGTTCG; positive control for CDX binding, CACAGCAAGATT-TATGACAAG (Taylor et al., 1997) ; positive control for RARE (Frasch et al., 1995) , TAATCTCAGGTTCACC-GAAAGTTCAAGAC.
